Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24845157 | 0.83 | KDM5B (0.52) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL31478624 | 0.81 | KDM5B (0.46) | ALDH1A1KDM5BKDM4AKDM5AKDM4C | |
| SCHEMBL26276579 | 0.80 | KDM5B (0.50) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL22718313 | 0.80 | KDM5B (0.50) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL24845233 | 0.80 | KDM5B (0.50) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL31331998 | 0.80 | KDM5B (0.50) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL22747288 | 0.78 | KDM5B (0.48) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL9714348 | 0.77 | KDM5B (0.54) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL22747342 | 0.76 | KDM5B (0.47) | ALDH1A1MEN1KMT2AKDM5BL3MBTL1 | |
| SCHEMBL2972635 | 0.75 | HPGDS (0.51) | KDM5BMAPTKDM5AKDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | claimed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | claimed |
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER INC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | APP, PSEN1, BACE1 | ALDH1A1 807/4885MEN1 485/4885KMT2A 2322/4885 |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | APP, PSEN1, BACE1 | ALDH1A1 807/4885MEN1 485/4885KMT2A 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.